You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.
The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.
The company said revenues in its diagnostics business unit rose 62 percent during the quarter.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.
The company agreed to settle a lawsuit alleging it improperly billed government health plans for its genetic tests.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.